Annual EBITDA
-$54.70 M
-$7.28 M-15.35%
December 31, 2022
Summary
- As of February 10, 2025, NBRV annual EBITDA is -$54.70 million, with the most recent change of -$7.28 million (-15.35%) on December 31, 2022.
- During the last 3 years, NBRV annual EBITDA has risen by +$24.02 million (+30.51%).
Performance
NBRV EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly EBITDA
-$8.48 M
+$13.82 M+61.96%
March 31, 2023
Summary
- As of February 10, 2025, NBRV quarterly EBITDA is -$8.48 million, with the most recent change of +$13.82 million (+61.96%) on March 31, 2023.
- Over the past year, NBRV quarterly EBITDA has increased by +$2.69 million (+24.05%).
Performance
NBRV Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM EBITDA
-$52.02 M
+$2.69 M+4.91%
March 31, 2023
Summary
- As of February 10, 2025, NBRV TTM EBITDA is -$52.02 million, with the most recent change of +$2.69 million (+4.91%) on March 31, 2023.
- Over the past year, NBRV TTM EBITDA has dropped by -$6.72 million (-14.84%).
Performance
NBRV TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NBRV EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -15.3% | +24.1% | -14.8% |
| 3 y3 years | +30.5% | +61.4% | +36.4% |
| 5 y5 years | +24.6% | +33.2% | +33.9% |
NBRV EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | +15.4% | at low | at high | +162.9% | +15.6% | +5.2% |
| 5 y | 5-year | +15.4% | +43.9% | at high | +162.9% | +15.6% | +57.2% |
| alltime | all time | -345.3% | +108.6% | -327.4% | +522.7% | +2554.1% | +136.9% |
Nabriva Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$8.48 M(-62.0%) | -$52.02 M(-4.9%) |
| Dec 2022 | -$54.70 M(+15.4%) | -$22.30 M(+106.3%) | -$54.70 M(+21.0%) |
| Sep 2022 | - | -$10.81 M(+3.8%) | -$45.20 M(+0.5%) |
| Jun 2022 | - | -$10.41 M(-6.8%) | -$44.99 M(-0.7%) |
| Mar 2022 | - | -$11.17 M(-12.8%) | -$45.29 M(-4.5%) |
| Dec 2021 | -$47.42 M(-29.1%) | -$12.81 M(+20.8%) | -$47.42 M(-8.9%) |
| Sep 2021 | - | -$10.60 M(-1.0%) | -$52.06 M(-3.6%) |
| Jun 2021 | - | -$10.71 M(-19.5%) | -$54.03 M(-7.0%) |
| Mar 2021 | - | -$13.30 M(-23.8%) | -$58.13 M(-13.0%) |
| Dec 2020 | -$66.88 M(-15.0%) | -$17.45 M(+38.8%) | -$66.80 M(-6.4%) |
| Sep 2020 | - | -$12.57 M(-15.1%) | -$71.39 M(-6.0%) |
| Jun 2020 | - | -$14.81 M(-32.6%) | -$75.93 M(-7.1%) |
| Mar 2020 | - | -$21.96 M(-0.4%) | -$81.75 M(+3.9%) |
| Dec 2019 | -$78.72 M(-31.0%) | -$22.05 M(+28.8%) | -$78.72 M(-10.1%) |
| Sep 2019 | - | -$17.11 M(-17.0%) | -$87.52 M(-29.0%) |
| Jun 2019 | - | -$20.63 M(+9.0%) | -$123.25 M(+2.4%) |
| Mar 2019 | - | -$18.93 M(-38.6%) | -$120.32 M(+5.5%) |
| Dec 2018 | -$114.09 M | -$30.85 M(-41.6%) | -$114.09 M(+8.4%) |
| Sep 2018 | - | -$52.84 M(+198.5%) | -$105.27 M(+44.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | - | -$17.70 M(+39.4%) | -$72.64 M(+3.1%) |
| Mar 2018 | - | -$12.70 M(-42.3%) | -$70.43 M(-2.9%) |
| Dec 2017 | -$72.53 M(+31.3%) | -$22.03 M(+9.0%) | -$72.53 M(+9.5%) |
| Sep 2017 | - | -$20.21 M(+30.4%) | -$66.26 M(+10.6%) |
| Jun 2017 | - | -$15.49 M(+4.7%) | -$59.91 M(+6.1%) |
| Mar 2017 | - | -$14.80 M(-6.1%) | -$56.48 M(+2.2%) |
| Dec 2016 | -$55.25 M(+119.6%) | -$15.76 M(+13.7%) | -$55.25 M(+24.3%) |
| Sep 2016 | - | -$13.86 M(+14.9%) | -$44.46 M(+14.4%) |
| Jun 2016 | - | -$12.06 M(-11.1%) | -$38.87 M(+20.3%) |
| Mar 2016 | - | -$13.57 M(+173.4%) | -$32.32 M(+115.2%) |
| Dec 2015 | -$25.16 M(+127.7%) | -$4.96 M(-40.0%) | -$15.02 M(-10.4%) |
| Sep 2015 | - | -$8.28 M(+50.3%) | -$16.77 M(+59.6%) |
| Jun 2015 | - | -$5.51 M(-247.6%) | -$10.51 M(+93.1%) |
| Mar 2015 | - | $3.73 M(-155.6%) | -$5.44 M(-51.1%) |
| Dec 2014 | -$11.05 M(-149.6%) | -$6.72 M(+232.8%) | -$11.13 M(+152.0%) |
| Sep 2014 | - | -$2.02 M(+358.6%) | -$4.42 M(+84.1%) |
| Jun 2014 | - | -$440.00 K(-77.5%) | -$2.40 M(+22.5%) |
| Mar 2014 | - | -$1.96 M | -$1.96 M |
| Dec 2013 | $22.30 M | - | - |
FAQ
- What is Nabriva Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Nabriva Therapeutics?
- What is Nabriva Therapeutics annual EBITDA year-on-year change?
- What is Nabriva Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Nabriva Therapeutics?
- What is Nabriva Therapeutics quarterly EBITDA year-on-year change?
- What is Nabriva Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Nabriva Therapeutics?
- What is Nabriva Therapeutics TTM EBITDA year-on-year change?
What is Nabriva Therapeutics annual EBITDA?
The current annual EBITDA of NBRV is -$54.70 M
What is the all time high annual EBITDA for Nabriva Therapeutics?
Nabriva Therapeutics all-time high annual EBITDA is $22.30 M
What is Nabriva Therapeutics annual EBITDA year-on-year change?
Over the past year, NBRV annual EBITDA has changed by -$7.28 M (-15.35%)
What is Nabriva Therapeutics quarterly EBITDA?
The current quarterly EBITDA of NBRV is -$8.48 M
What is the all time high quarterly EBITDA for Nabriva Therapeutics?
Nabriva Therapeutics all-time high quarterly EBITDA is $3.73 M
What is Nabriva Therapeutics quarterly EBITDA year-on-year change?
Over the past year, NBRV quarterly EBITDA has changed by +$2.69 M (+24.05%)
What is Nabriva Therapeutics TTM EBITDA?
The current TTM EBITDA of NBRV is -$52.02 M
What is the all time high TTM EBITDA for Nabriva Therapeutics?
Nabriva Therapeutics all-time high TTM EBITDA is -$1.96 M
What is Nabriva Therapeutics TTM EBITDA year-on-year change?
Over the past year, NBRV TTM EBITDA has changed by -$6.72 M (-14.84%)